- Home
- PHAR vs RES Comparison
PHAR vs RES Comparison
Compare PHAR & RES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- RES
- Stock Information
- Founded
- PHAR 1988
- RES 1984
- Country
- PHAR Netherlands
- RES United States
- Employees
- PHAR N/A
- RES N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- RES Oilfield Services/Equipment
- Sector
- PHAR Health Care
- RES Energy
- Exchange
- PHAR Nasdaq
- RES Nasdaq
- Market Cap
- PHAR 951.7M
- RES 997.2M
- IPO Year
- PHAR N/A
- RES N/A
- Fundamental
- Price
- PHAR $13.18
- RES $5.41
- Analyst Decision
- PHAR Strong Buy
- RES Hold
- Analyst Count
- PHAR 3
- RES 5
- Target Price
- PHAR $30.00
- RES $4.99
- AVG Volume (30 Days)
- PHAR 9.7K
- RES 1.6M
- Earning Date
- PHAR 11-06-2025
- RES 10-30-2025
- Dividend Yield
- PHAR N/A
- RES 2.96%
- EPS Growth
- PHAR N/A
- RES N/A
- EPS
- PHAR N/A
- RES 0.22
- Revenue
- PHAR $339,836,000.00
- RES $1,536,150,000.00
- Revenue This Year
- PHAR $17.70
- RES $10.46
- Revenue Next Year
- PHAR $12.25
- RES $5.82
- P/E Ratio
- PHAR N/A
- RES $24.83
- Revenue Growth
- PHAR 22.44
- RES 4.20
- 52 Week Low
- PHAR $7.31
- RES $4.10
- 52 Week High
- PHAR $17.08
- RES $7.17
- Technical
- Relative Strength Index (RSI)
- PHAR 43.85
- RES 66.88
- Support Level
- PHAR $13.03
- RES $4.74
- Resistance Level
- PHAR $13.43
- RES $5.58
- Average True Range (ATR)
- PHAR 0.49
- RES 0.21
- MACD
- PHAR -0.10
- RES 0.09
- Stochastic Oscillator
- PHAR 23.47
- RES 86.03
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About RES RPC Inc.
RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.